Tag
NYSE: MRK
- Xencor reports 45.5% confirmed response at selected kidney-cancer dose
- Pfizer details 25‑strain infant vaccine data as pivotal trials advance
- Roche Holding AG gains FDA approval for Tecentriq in stage III dMMR colon cancer
- Vaxcyte prices US$1B in stock, warrants and convertible notes
- Vaxcyte reports VAX‑31 met all OPUS‑1 primary immune endpoints
- Surrozen gains FDA IND clearance for SZN‑8141 macular edema trial
- Merck closes SciBrunch KRAS licence worth up to US$2.13B
- Merck and Daiichi Sankyo withdraw ifinatamab deruxtecan BLA
- Merck says remigromig met BRUNELLO vision endpoint, flags eye risks
- Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss
- Scribe Therapeutics develops one‑time cholesterol treatment without permanent gene editing
- Cambridge researchers develop urine test that could detect lung cancer years earlier
- New blood test approach could detect multiple cancers earlier, researchers say
- Enliven Therapeutics stock climbs on upgrades, sector validation from Merck acquisition
- Oregon State nanomaterial eradicates breast cancer tumours in mice
- Illumina partners with pharma giants to map disease biology at unprecedented scale
- Lung cancer awareness month: a Mugglehead roundup
- Evaxion shares spike as AI‑designed melanoma vaccine data hits market
- Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug
- Puma Biotechnology shares get favourable price bump on strong Q2 results
- CG Oncology shares jump on positive clinical trial data for cancer drug
- Personalis Inc share price jumps 50% on deals with Merck and Moderna
- NetraMark demonstrates efficacy of AI to help with clinical trials